Reference health
Inflammatory signaling mechanisms in bipolar disorder
187/187 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 187 checked references that resolve
resolves10.1016/j.jad.2016.12.059
Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems
resolves10.1016/j.jad.2014.08.052
General medical conditions in 347 bipolar disorder patients: Clinical correlates of metabolic and autoimmune-allergic diseases
resolves10.1017/S1461145709009924
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder
resolves10.1016/j.pnpbp.2006.09.010
High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania
resolves10.1192/bjp.2018.144
Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses
resolves10.1016/j.psychres.2015.05.078
Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment
resolves10.1089/cap.2011.0009
Preliminary Findings Regarding Proinflammatory Markers and Brain-Derived Neurotrophic Factor Among Adolescents with Bipolar Spectrum Disorders
resolves10.1016/j.pnpbp.2014.01.013
Inflamed moods: A review of the interactions between inflammation and mood disorders
resolves10.1038/tp.2014.8
Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder
resolves10.1016/j.jad.2012.09.017
Neurocognitive functioning in the prodrome of mania—an exploratory study
resolves10.1016/j.neubiorev.2010.10.001
Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors
resolves10.1097/YCO.0b013e32835aa4b4
Is bipolar disorder an inflammatory condition? The relevance of microglial activation
resolves10.1093/schbul/sbw183
A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue
resolves10.1016/j.jad.2012.04.044
Evidence for an association between tumor necrosis factor-alpha levels and lithium response
resolves10.1016/j.schres.2012.12.023
Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder
resolves10.1038/s41375-019-0436-6
NLRP3 inflammasome couples purinergic signaling with activation of the complement cascade for the optimal release of cells from bone marrow
resolves10.3389/fpsyt.2018.00614
Assessment of Complement Cascade Components in Patients With Bipolar Disorder
resolves10.1007/s12015-019-09888-1
ATP-Nlrp3 Inflammasome-Complement Cascade Axis in Sterile Brain Inflammation in Psychiatric Patients and its Impact on Stem Cell Trafficking
resolves10.1016/j.pnpbp.2017.04.005
Adult stem cells in psychiatric disorders – New discoveries in peripheral blood
resolves10.1017/neu.2017.10
Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels
resolves10.1038/nature08185
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
resolves10.2174/1381612822666151214105314
Bipolar Disorder: The Role of the Kynurenine and Melatonergic Pathways
resolves10.1038/mp.2009.47
Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients
resolves10.1016/j.bbi.2014.03.016
Neuroinflammation in bipolar disorder – A [11C]-(R)-PK11195 positron emission tomography study
resolves10.1503/jpn.140183
Monocyte and microglial activation in patients with mood-stabilized bipolar disorder
resolves10.1111/bdi.12231
Monocyte activation, brain‐derived neurotrophic factor (<scp>BDNF</scp>), and S100B in bipolar offspring: a follow‐up study from adolescence into adulthood
resolves10.1016/j.bbi.2016.05.007
A dynamic course of T cell defects in individuals at risk for mood disorders
resolves10.1177/0269881117725711
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
resolves10.1111/bdi.12373
Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis
resolves10.1007/s40263-014-0158-2
PPAR-γ Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar Depression
resolves10.1038/s41398-017-0073-7
Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial
resolves10.1111/j.1399-5618.2011.00945.x
Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials
resolves10.1001/2013.jamapsychiatry.4
A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
resolves10.1016/j.bbi.2018.08.009
C-reactive protein and response to lurasidone in patients with bipolar depression
resolves10.1016/j.biopsych.2018.03.004
Mitochondrial Dysfunction: At the Core of Psychiatric Disorders?
resolves10.1016/j.neubiorev.2016.06.040
Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications
resolves10.2353/ajpath.2010.081068
Abnormalities in Mitochondrial Structure in Cells from Patients with Bipolar Disorder
resolves10.1038/srep15962
Dynamin-related protein 1 controls the migration and neuronal differentiation of subventricular zone-derived neural progenitor cells
resolves10.1038/npp.2017.32
Hippocampus Glutamate and N-Acetyl Aspartate Markers of Excitotoxic Neuronal Compromise in Posttraumatic Stress Disorder
resolves10.1016/j.neulet.2007.05.016
Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects
resolves10.1016/j.psychres.2014.04.005
An updated meta-analysis of oxidative stress markers in bipolar disorder
resolves10.1016/j.jpsychires.2015.01.016
Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes
resolves10.1097/JCP.0000000000000616
Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder
resolves10.1007/s00213-014-3655-6
Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes
resolves10.1016/j.immuni.2012.01.009
Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis
resolves10.1038/s41380-019-0622-y
Cellular calcium in bipolar disorder: systematic review and meta-analysis
resolves10.1038/mp.2014.143
Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons
resolves10.1038/nature15526
Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder
resolves10.1016/j.biopsych.2006.03.032
Differential Expression of Disrupted-in-Schizophrenia (DISC1) in Bipolar Disorder
resolves10.1007/s12325-017-0482-2
The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder
resolves10.1186/s12929-018-0473-x
The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions
resolves10.3389/fpsyt.2012.00025
DISC1 Pathway in Brain Development: Exploring Therapeutic Targets for Major Psychiatric Disorders
resolves10.3389/fncel.2018.00314
Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases
resolves10.1002/syn.21549
Sigma‐1 receptor chaperones regulate the secretion of brain‐derived neurotrophic factor
resolves10.1016/j.jphs.2014.11.010
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication
resolves10.1016/j.cell.2007.08.036
Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival
resolves10.3389/fncel.2020.554548
The Unfolded Protein Response and Autophagy as Drug Targets in Neuropsychiatric Disorders
resolves10.1016/j.pneurobio.2012.09.001
Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression
resolves10.1016/j.jphs.2014.07.001
Sigma-1 receptor: The novel intracellular target of neuropsychotherapeutic drugs
resolves10.1074/jbc.274.10.6039
Long Term Lithium Treatment Suppresses p53 and Bax Expression but Increases Bcl-2 Expression
resolves10.1124/mol.108.052357
Lithium Increases Synapse Formation between Hippocampal Neurons by Depleting Phosphoinositides
resolves10.1155/2019/3462530
ER Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis
resolves10.1146/annurev-immunol-031210-101405
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
resolves10.1016/j.jpsychires.2015.10.015
Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation
resolves10.4049/jimmunol.1200312
Cutting Edge: miR-223 and EBV miR-BART15 Regulate the NLRP3 Inflammasome and IL-1β Production
resolves10.1074/jbc.M116.772947
The RNA-binding protein Tristetraprolin (TTP) is a critical negative regulator of the NLRP3 inflammasome
resolves10.1016/j.jad.2011.08.022
Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder
resolves10.1111/bdi.12214
Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin‐releasing hormone and interleukin‐1β?
resolves10.1016/j.canlet.2018.01.034
The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways
resolves10.4088/JCP.v69n0806
A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania
resolves10.1002/da.22340
PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
resolves10.1016/j.phrs.2017.04.028
Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder
resolves10.1007/s11064-014-1241-2
Valproic Acid: A New Candidate of Therapeutic Application for the Acute Central Nervous System Injuries
resolves10.3390/cells9030577
Clozapine Prevents Poly (I:C) Induced Inflammation by Modulating NLRP3 Pathway in Microglial Cells
resolves10.1186/s13578-020-00388-1
P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes
resolves10.3389/fphar.2020.578396
The Ketogenic Diet for the Treatment of Mood Disorders in Comorbidity With Epilepsy in Children and Adolescents
resolves10.1016/j.yebeh.2016.04.033
Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: A randomized controlled trial
resolves10.1038/s41598-017-08055-1
Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses
resolves10.1016/j.pnpbp.2014.10.016
Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics
resolves10.1016/j.pnpbp.2010.02.027
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode
resolves10.1016/j.jad.2009.05.023
Association of serum uric acid levels with emotional and affective temperaments
resolves10.1016/j.biopsych.2013.02.024
Impulsivity is Associated with Uric Acid: Evidence from Humans and Mice
resolves10.1111/bdi.12708
Serum uric acid as a predictor of bipolarity in individuals with a major depressive episode
resolves10.1080/14737159.2017.1270758
Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder
resolves10.1016/j.pnpbp.2006.02.002
Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications
resolves10.1016/j.mam.2016.12.001
Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
resolves10.1155/2018/7019398
The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases
resolves10.1192/bjp.bp.115.180281
Allopurinol as add-on treatment for mania symptoms in bipolar disorder: Systematic review and meta-analysis of randomised controlled trials
resolves10.1097/00004850-200301000-00009
Allopurinol for the treatment of aggressive behaviour in patients with dementia
resolves10.1002/glia.22904
Mechanism of microglia neuroprotection: Involvement of<scp>P2X</scp>7,<scp>TNF</scp>α, and valproic acid
resolves10.1016/j.biopsych.2015.11.026
Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor
resolves10.3389/fphar.2018.00030
Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders
resolves10.1038/d41573-020-00049-5
Can anti-inflammatory strategies light up the dim depression pipeline?
resolves10.1038/s41380-019-0589-8
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response
resolves10.3389/fimmu.2017.01957
Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions
resolves10.1016/j.bbi.2019.02.009
Kynurenic acid/GPR35 axis restricts NLRP3 inflammasome activation and exacerbates colitis in mice with social stress
resolves10.1111/bdi.12814
A mood state‐specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder
resolves10.1038/npp.2013.140
Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression
resolves10.1016/j.drudis.2018.11.007
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
resolves10.1038/s41380-018-0076-7
Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice
resolves10.1021/acs.jmedchem.5b00461
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
resolves10.1080/07420528.2018.1487975
The neurobiology of adaptation to seasons: Relevance and correlations in bipolar disorders
resolves10.1002/da.22084
CYTOKINE TARGETS IN THE BRAIN: IMPACT ON NEUROTRANSMITTERS AND NEUROCIRCUITS
resolves10.2147/NDT.S109835
Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode
resolves10.1111/j.1399-5618.2007.00528.x
Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder
resolves10.2174/1381612824666180803112304
Circadian Rhythm and Melatonin in the Treatment of Depression
resolves10.9758/cpn.2018.16.3.235
Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials
resolves10.1192/bjp.184.6.496
Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder
resolves10.1016/j.psyneuen.2018.09.020
Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives
resolves10.1016/S0306-4530(02)00135-X
High levels of cortisol among adolescent offspring of parents with bipolar disorder: a pilot study
resolves10.2174/1566524015666150330143008
Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders
resolves10.1016/j.brainres.2004.11.014
TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition
resolves10.1016/j.neurobiolaging.2016.04.014
Insensitivity of astrocytes to interleukin 10 signaling following peripheral immune challenge results in prolonged microglial activation in the aged brain
resolves10.4161/cib.13761
Cooperation between BDNF and glutamate in the regulation of synaptic transmission and neuronal development
resolves10.1016/j.bbi.2019.07.003
Interplay between inflammation and neural plasticity: Both immune activation and suppression impair LTP and BDNF expression
resolves10.1152/ajpheart.00224.2013
Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice
resolves10.1152/physiolgenomics.00165.2005
BDNF-mediated enhancement of inflammation and injury in the aging heart
resolves10.1016/j.eurpsy.2019.02.006
High BDNF serum levels are associated to good cognitive functioning in bipolar disorder
resolves10.1007/s10571-019-00684-6
The Missing Link: How Exosomes and miRNAs can Help in Bridging Psychiatry and Molecular Biology in the Context of Depression, Bipolar Disorder and Schizophrenia
resolves10.1038/srep42755
Antisense miR-132 blockade via the AChE-R splice variant mitigates cortical inflammation
resolves10.3389/fpsyt.2019.00066
Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study
resolves10.1177/0269881114563634
Glutamate and dopamine in schizophrenia: An update for the 21
<sup>st</sup>
century
resolves10.3389/fpsyt.2018.00767
Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies
resolves10.1016/j.schres.2013.03.015
Human brain imaging studies of DISC1 in schizophrenia, bipolar disorder and depression: A systematic review
resolves10.1038/s41386-020-0644-9
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
resolves10.1016/j.phrs.2021.105586
The interaction between autophagy and neuroinflammation in major depressive disorder: From pathophysiology to therapeutic implications
resolves10.1016/j.cyto.2011.06.022
Effect of N-methyl-D-aspartate receptor antagonist on T helper cell differentiation induced by phorbol-myristate-acetate and ionomycin
resolves10.1016/j.biopsych.2014.06.021
Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression
resolves10.1038/tp.2017.31
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome
resolves10.1016/j.jpsychires.2016.09.025
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression
resolves10.1016/j.psychres.2018.08.078
Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study
resolves10.1038/s41398-021-01268-z
Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers
resolves10.1093/ijnp/pyaa087
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
resolves10.1038/nrn2884
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
resolves10.1007/s00213-013-3024-x
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
resolves10.1016/j.jad.2016.09.008
Continuation phase intravenous ketamine in adults with treatment-resistant depression
resolves10.1016/j.lfs.2019.116790
5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model
resolves10.1371/journal.pone.0075426
Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo
resolves10.1124/jpet.108.143461
Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency
resolves10.1177/0269881120936486
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
The 7 references without a DOI — listed, not checked
no DOI — not checkedGoodwin F, Jamison K. Manic-Depressive Illness (Second Ed.). Oxford University Press; 2007. Accessed February 7, 2021. https://global.oup.com/academic/product/manic-depressive-illness-9780195135794?cc=us&lang=en&
no DOI — not checkedImpact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Schizophrenia or Bipolar Illness - Full Text View - ClinicalTrials.gov. Accessed April 10, 2021. https://clinicaltrials.gov/ct2/show/NCT03935854?cond=ketogenic+diet+bipolar+disorder&draw=2&rank=1
no DOI — not checkedDe Berardis D, Carano A, Valchera A, San V, Hospital G, Piceno A. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder emotions & embodiment view project glutamatergic system in the treatment of Major Depression View Project; 2008. Accessed February 7, 2021. https://www.researchgate.net/publication/23306566
no DOI — not checkedCervantes P, Gelber S, Ng Y, Kin FNK, Nair VNP, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci. 2001;26(5):411–6.
no DOI — not checkedJones GH, Rong C, Shariq AS, Mishra A, Machado-Vieira R. Intracellular signaling cascades in bipolar disorder. Berlin: Springer; 2020.
no DOI — not checkedThe Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. - Full Text View - ClinicalTrials.gov. Accessed May 22, 2021. https://clinicaltrials.gov/ct2/show/NCT04433845
no DOI — not checkedMarek GJ. Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons. Current topics in behavioral neurosciences. New York: Springer; 2018.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1186/s12929-021-00742-6"><img src="https://citestamp.com/citestamped/10.1186/s12929-021-00742-6/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1186/s12929-021-00742-6)